SG Americas Securities LLC increased its position in Novartis AG (NYSE:NVS) by 48.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,505 shares of the company’s stock after buying an additional 7,003 shares during the period. SG Americas Securities LLC’s holdings in Novartis AG were worth $1,795,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. City Holding Co. boosted its position in Novartis AG by 4.6% in the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after buying an additional 54 shares during the last quarter. TCI Wealth Advisors Inc. boosted its position in Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock valued at $103,000 after buying an additional 230 shares during the last quarter. Archford Capital Strategies LLC boosted its position in Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after buying an additional 621 shares during the last quarter. Kernodle & Katon Asset Management Group LLC boosted its position in Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after buying an additional 49 shares during the last quarter. Finally, North Star Investment Management Corp. boosted its position in Novartis AG by 50.3% in the first quarter. North Star Investment Management Corp. now owns 1,526 shares of the company’s stock valued at $113,000 after buying an additional 511 shares during the last quarter. Hedge funds and other institutional investors own 10.97% of the company’s stock.

Shares of Novartis AG (NYSE NVS) opened at 83.53 on Monday. The stock has a 50 day moving average price of $83.94 and a 200 day moving average price of $79.45. Novartis AG has a one year low of $66.93 and a one year high of $86.90. The firm has a market cap of $195.70 billion, a price-to-earnings ratio of 30.50 and a beta of 0.73.

Novartis AG (NYSE:NVS) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.06. The business had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. Novartis AG’s quarterly revenue was down 1.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.23 earnings per share. On average, equities research analysts forecast that Novartis AG will post $4.74 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “SG Americas Securities LLC Buys 7,003 Shares of Novartis AG (NVS)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/28/sg-americas-securities-llc-buys-7003-shares-of-novartis-ag-nvs.html.

Several research analysts have recently issued reports on NVS shares. Zacks Investment Research cut Novartis AG from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Credit Suisse Group cut Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 price target for the company. in a research note on Wednesday, July 5th. Morgan Stanley raised Novartis AG from an “underweight” rating to an “overweight” rating in a research note on Wednesday, July 26th. Leerink Swann reissued a “market perform” rating and issued a $83.00 price target on shares of Novartis AG in a research note on Thursday, June 22nd. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Novartis AG in a research note on Friday, June 2nd. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the stock. Novartis AG presently has a consensus rating of “Hold” and a consensus price target of $83.56.

In related news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the firm’s stock in a transaction that occurred on Wednesday, July 5th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.01% of the company’s stock.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.